367 related articles for article (PubMed ID: 27411914)
1. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
Hsu LH; Hsu PC; Liao TL; Feng AC; Chu NM; Kao SH
BMC Cancer; 2016 Jul; 16():463. PubMed ID: 27411914
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-β1 rise in pleural fluid after tunneled pleural catheter placement: pilot study.
Shojaee S; Voelkel N; Farkas L; de Wit M; Lee HJ
J Bronchology Interv Pulmonol; 2013 Oct; 20(4):304-8. PubMed ID: 24162112
[TBL] [Abstract][Full Text] [Related]
3. VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes.
Hooper CE; Elvers KT; Welsh GI; Millar AB; Maskell NA
Lung Cancer; 2012 Aug; 77(2):443-9. PubMed ID: 22487430
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
5. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of chemical pleurodesis using a minocycline.
Hsu LH; Feng AC; Soong TC; Ko JS; Chu NM; Lin YF; Kao SH
Ther Adv Respir Dis; 2019; 13():1753466619841231. PubMed ID: 30945619
[TBL] [Abstract][Full Text] [Related]
7. [The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion].
Zhu QQ; Sun GY
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep; 32(9):674-8. PubMed ID: 20079281
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
9. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
Lumachi F; Mazza F; Ermani M; Chiara GB; Basso SM
Anticancer Res; 2012 Nov; 32(11):5071-4. PubMed ID: 23155281
[TBL] [Abstract][Full Text] [Related]
10. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
11. Survivin is a negative prognostic factor in malignant pleural effusion.
Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R
Eur J Clin Invest; 2018 Apr; 48(4):. PubMed ID: 29359509
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Vascular Endothelial Growth Factor, Transforming Growth Factor-β, Interleukin-8, and the Ratio of Lactate Dehydrogenase to Adenosine Deaminase in Pleural Effusion.
Saraya T; Ohkuma K; Watanabe T; Mikura S; Kobayashi F; Aso J; Nunokawa H; Honda K; Ogawa Y; Tamura M; Sada M; Oda M; Inoue M; Yokoyama T; Kurai D; Ishii H; Kimura H; Takizawa H
Lung; 2018 Apr; 196(2):249-254. PubMed ID: 29353318
[TBL] [Abstract][Full Text] [Related]
13. Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.
Mishra EK; Clive AO; Wills GH; Davies HE; Stanton AE; Al-Aloul M; Hart-Thomas A; Pepperell J; Evison M; Saba T; Harrison RN; Guhan A; Callister ME; Sathyamurthy R; Rehal S; Corcoran JP; Hallifax R; Psallidas I; Russell N; Shaw R; Dobson M; Wrightson JM; West A; Lee YCG; Nunn AJ; Miller RF; Maskell NA; Rahman NM
Am J Respir Crit Care Med; 2018 Feb; 197(4):502-508. PubMed ID: 28926296
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.
Psallidas I; Kanellakis NI; Gerry S; Thézénas ML; Charles PD; Samsonova A; Schiller HB; Fischer R; Asciak R; Hallifax RJ; Mercer R; Dobson M; Dong T; Pavord ID; Collins GS; Kessler BM; Pass HI; Maskell N; Stathopoulos GT; Rahman NM
Lancet Oncol; 2018 Jul; 19(7):930-939. PubMed ID: 29908990
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
[TBL] [Abstract][Full Text] [Related]
16. [Role of c-c chemokines in the determination of pleural effusion etiology].
Trzaska-Sobczak M; Pierzchała W; Brozek G; Farnik M
Wiad Lek; 2008; 61(7-9):190-4. PubMed ID: 19172830
[TBL] [Abstract][Full Text] [Related]
17. Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.
Korsic M; Badovinac S; Cucevic B; Janevski Z
Wien Klin Wochenschr; 2015 Dec; 127(23-24):963-9. PubMed ID: 25860847
[TBL] [Abstract][Full Text] [Related]
18. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
19. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion.
Fysh ETH; Waterer GW; Kendall PA; Bremner PR; Dina S; Geelhoed E; McCarney K; Morey S; Millward M; Musk AWB; Lee YCG
Chest; 2012 Aug; 142(2):394-400. PubMed ID: 22406960
[TBL] [Abstract][Full Text] [Related]
20. Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis.
Teixeira LR; Vargas FS; Acencio MM; Ribeiro SC; Sales RK; Antonangelo L; Marchi E
Lung Cancer; 2011 Dec; 74(3):392-5. PubMed ID: 21616551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
